Bob Herpen

1 week ago | healio.com | Bob Herpen

Key takeaways: The estimated added effect of provocation was not significant for either condition. The findings have implications for a variety of other psychiatric and substance use disorders. Transcranial magnetic stimulation with added symptom provocation was effective compared with sham for both obsessive-compulsive disorder and nicotine addiction, results of a systematic meta-analysis published in JAMA Psychiatry show.

2 weeks ago | healio.com | Bob Herpen

Key takeaways 50% of participants showed cognitive impairment No links were found between sleep-related symptoms and cognitive battery scores. Determining definitive links between sleep, memory and cognitive deficits among World Trade Center rescue and recovery workers requires more precise metrics for analysis, according to a poster presented at SLEEP 2025.

2 weeks ago | healio.com | Bob Herpen

Key takeaways: The Syn-One Test detected P-SYN presence in 75% of study participants during baseline evaluations. P-SYN positive individuals tended to be older and endured longer idiopathic REM sleep behavior disorder. A punch biopsy reliably detected a biomarker of neurodegenerative disease in a small cohort of older adults diagnosed with idiopathic REM sleep disorder, according to a poster presented at SLEEP 2025.

2 weeks ago | healio.com | Bob Herpen

Read more Key takeaways: Patients who started therapy within 6 months had better recovery than those who delayed therapy. Clinicians working with stroke survivors should screen and refer patients for therapy as soon as possible. Therapy for anxiety and depression after stroke was associated with improved recovery, with early treatment leading to better outcomes than delayed treatment, according to research published in Nature Mental Health.

2 weeks ago | healio.com | Bob Herpen |Feixiong Cheng

Key takeaways: Large-data AI models may also be used to identify non-FDA-approved drugs for Parkinson’s disease. There is potential for AI models to identify Parkinson’s drugs to treat other non-neurodegenerative conditions. AI may provide an answer to the question of whether drugs initially developed and prescribed for non-neurodegenerative physical conditions can be used to treat individuals with Parkinson’s disease.